General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews

The growing demand for improved pain treatments together with expanding legalization of, and access to, cannabinoids, cannabis, and cannabis-based medicines has intensified the focus on risk–benefit considerations in pain management. Given limited harms data from analgesic clinical trials, we conducted an overview of systematic reviews focused on all harms possibly relevant to patients receiving cannabinoids for pain management. This PROSPERO-registered, PRISMA-compliant systematic overview identified 79 reviews, encompassing over 2200 individual reports about psychiatric and psychosocial harms, cognitive/behavioral effects, motor vehicle accidents, cardiovascular, respiratory, cancer-related, maternal/fetal, and general harms. Reviews, and their included studies, were of variable quality. Available evidence suggests variable associations between cannabis exposure (ranging from monthly to daily use based largely on self-report) and psychosis, motor vehicle accidents, respiratory problems, and other harms. Most evidence comes from settings other than that of pain management (eg, nonmedicinal and experimental) but does signal a need for caution and more robust harms evaluation in future studies. Given partial overlap between patients receiving cannabinoids for pain management and individuals using cannabinoids for other reasons, lessons from the crisis of oversupply and overuse of opioids in some parts of the world emphasize the need to broadly consider harms evidence from real-world settings. The advancement of research on cannabinoid harms will serve to guide optimal approaches to the use of cannabinoids for pain management. In the meantime, this evidence should be carefully examined when making risk–benefit considerations about the use of cannabinoids, cannabis, and cannabis-based medicine for chronic pain.

Read the full article here: https://journals.lww.com/pain/Fulltext/2021/07001/General_risks_of_harm_with_cannabinoids,_cannabis,.7.aspx

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

WADA Executive Committee Approves 2023 Prohibited List

On September 23, the World Anti-Doping Agency’s (WADA’s) Executive Committee (ExCo) held its second meeting of the year in Sydney, Australia. ExCo members, some of whom attended in person and others virtually, were updated on WADA’s progress on key priorities, took a number of decisions – the main ones being summarized below – and made

Doctors Inform Parents of Marijuana Use Linked to Youth Mental Health

Dr. Roneet Lev, with Scripps Hospital Emergency Room, wants to make sure parents and youth are making informed decisions and understand the risks. During Thursday’s event, doctors laid out the relationship between marijuana use and youth mental health. Lev warned that cannabis use is a suicide risk factor for people under the age of 25.

Changes in Traffic Crash Rates After Legalization of Marijuana

Legalization of the recreational use of marijuana was associated with a 6.5% increase in injury crash rates and a 2.3% increase in fatal crash rates, but the subsequent onset of retail marijuana sales did not elicit additional substantial changes. Thus, the combined effect of legalization and retail sales was a 5.8% increase in injury crash

Legalized Marijuana is a Global Warming Nightmare

Leaders in the Democratic Party are backing legislation to reduce carbon emissions. Some of them are also sponsoring bills that would expand the cannabis industry, ranging from the MORE Act to the Safe Banking Act and now the Cannabis Administration and Opportunity Act just introduced by Senate Majority Leader Chuck Schumer (D-NY). Co-sponsors have publicly

Scroll to Top